1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
    Journal Article

    Mauro, M. J.; Hughes, T. P.; Kim, D. W.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Sasaki, K.; Breccia, M.; Talpaz, M.; Ottmann, O.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
    Journal Article

    Lesokhin, A.; LeBlanc, R.; Dimopoulos, M. A.; Capra, M.; Carlo-Stella, C.; Karlin, L.; Castilloux, J. F.; Forsberg, P.; Parmar, G.; Tosikyan, A.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save
  • Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
    Journal Article

    Krishnan, A.; Nooka, A. K.; Chari, A.; Garfall, A. L.; Martin, T. G.; Nair, S.; Lin, X.; Qi, K.; Londhe, A.; Pei, L.; more...
    Journal of Comparative Effectiveness Research (2023)

    Fulltext@MSK | Save
  • Myosin light-chain kinase inhibition potentiates the antitumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor
    Journal Article

    Rossi, F.; Liu, M.; Tieniber, A.; Etherington, M. S.; Hanna, A.; Vitiello, G. A.; Param, N. J.; Do, K.; Wang, L.; Antonescu, C. R.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
    Journal Article

    Yu, K. H.; Cockrum, P.; Surinach, A.; Lamarre, N.; Wang, S.; O'Reilly, E. M.
    Cancer Medicine (2023)

    Fulltext@MSK | Save
  • Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
    Journal Article

    Diamond, B.; Ziccheddu, B.; Maclachlan, K.; Taylor, J.; Boyle, E.; Ossa, J. A.; Jahn, J.; Affer, M.; Totiger, T. M.; Coffey, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
    Journal Article

    Issa, G. C.; Aldoss, I.; DiPersio, J.; Cuglievan, B.; Stone, R.; Arellano, M.; Thirman, M. J.; Patel, M. R.; Dickens, D. S.; Shenoy, S.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Moving towards biologically informed treatment strategies for T-cell lymphomas
    Review

    Stuver, R.; Lewis, N.; Dogan, A.; Horwitz, S. M.
    International Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Comparing the effects of rocaglates on energy metabolism and immune modulation on cells of the human immune system
    Journal Article

    Schiffmann, S.; Henke, M.; Seifert, M.; Ulshöfer, T.; Roser, L. A.; Magari, F.; Wendel, H. G.; Grünweller, A.; Parnham, M. J.
    International Journal of Molecular Sciences (2023)

    Fulltext@MSK | Save
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save